HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Lupin Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Lupin Ltd Stock Comparison

Last Updated on: Jun 08, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1320 as of 06 Jun 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 38.5 on March 2024 . This represents a CAGR of 0.26% over 4 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 26713 crore on March 2020 to ₹ 73722 crore on March 2024 . This represents a CAGR of 22.51% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of Lupin Ltd for the Mar '25 is ₹ 5724 crore as compare to the Dec '24 revenue of ₹ 5821 crore. This represent the decline of -1.67%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of Lupin Ltd for the Mar '25 is ₹ 1378 crore as compare to the Dec '24 ebitda of ₹ 1409 crore. This represent the decline of -2.23%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of Lupin Ltd changed from ₹ 453.33 crore to ₹ 782.38 crore over 8 quarters. This represents a CAGR of 31.37% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 37.36 % on March 2020 to 15.67 % on March 2024 . This represents a CAGR of -15.95% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Lupin Ltd

  • Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
  • The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
  • In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
  • In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

Dr Reddys Laboratories Ltd News Hub

News

Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu...

Read more

05 Jun 2025 09:20

News

Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $...

Read more

05 Jun 2025 10:10

News

Dr Reddys Laboratories allots 57,840 equity shares under ESOS

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fu...

Read more

03 Jun 2025 16:28

News

Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FD...

Read more

26 May 2025 09:33

News

DRL's USA facility gets 2 observations from USFDA

The USFDA completed aforementioned inspection and issued form-483 with two observations. H...

Read more

19 May 2025 08:32

News

USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York

Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA)...

Read more

17 May 2025 11:32

Lupin Ltd News Hub

News

Lupin allots 78,930 equity shares under ESOP

Lupin has allotted 78,930 equity shares under Stock Option plans of the Company. According...

Read more

27 May 2025 15:33

News

Lupin grants 7,337 stock options

Lupin has granted 7,337 stock options on 27 May 2025. Please note that upon vesting, one s...

Read more

27 May 2025 18:42

News

Lupin enters into license and supply agreement with SteinCares

Lupin has entered into a license and supply agreement with SteinCares, a leading specialty...

Read more

26 May 2025 10:27

News

Lupin to develop next-gen inhalers using Honeywell's Solstice' Air propellant

Lupin announced today its plan to use Honeywell's Solstice' Air (HFO-1234ze cGMP) propella...

Read more

20 May 2025 19:07

News

Board of Lupin recommends final dividend

Lupin announced that the Board of Directors of the Company at its meeting held on 14 May 2...

Read more

15 May 2025 10:06

News

Lupin receives USFDA approval for Rivaroxaban Tablets

Lupin announced that it has received approval from the United States Food and Drug Adminis...

Read more

15 May 2025 16:21

SWOT Analysis Of Lupin Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lupin Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Lupin Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Lupin Ltd?

Market cap of Dr Reddys Laboratories Ltd is 110,189 Cr while Market cap of Lupin Ltd is 91,302 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Lupin Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Lupin Ltd?

As of June 8, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1320.5. On the other hand, Lupin Ltd stock price is INR ₹1999.2.

How do dividend payouts of Dr Reddys Laboratories Ltd and Lupin Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions